← 產業報告目錄

PEGylated Drugs Market Research Report Information by Molecule (Macromolecular Drugs, Small Molecular Drugs and Lipid Nanoparticles (LNP) and Liposomes), by Application (Oncology, Neurology, Autoimmune Diseases, Haematology and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) Forecast till 2035

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2025-02-20頁數 175報告編號 MRFRHC6964CR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

PEGylated Drugs Market Research Report Information by Molecule (Macromolecular Drugs, Small Molecular Drugs and Lipid Nanoparticles (LNP) and Liposomes), by Application (Oncology, Neurology, Autoimmune Diseases, Haematology and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) Forecast till 2035 Overview of the Market During the assessment period, the PEGylated Drugs Market is expected to grow at a noteworthy CAGR of 5.17%. The process by which covalent and non-covalent glycol polymer chains bind to bioactive substances such proteins, peptides, enzymes, oligonucleotides, and antibody fragments is known as pegylation. In a clinical setting, it is a safe method for boosting the therapeutic effectiveness of medications. Numerous FDA-approved pegylated medications are used in clinical settings. The global pegylated market is expanding due to the rising prevalence of chronic illnesses, developments in biologics, and newly approved pegylated medications. The market is also constrained by high production costs, regulatory obstacles, and possible adverse consequences. However, the industry will have future development prospects due to customized medicine, expanding markets, and cutting-edge drug delivery technologies. The study includes a thorough analysis of the pegylated antibody's advantages, market expansion, motivating factors, and difficulties. It also highlights the main players in the PEGylated Proteins Market, their contributions, and their advancements. The development of biologics industries, the rise in the prevalence of diseases like cancer, and the expansion of pharmaceutical industries worldwide are the primary factors propelling the PEGylated Drugs Market. Furthermore, Canada's rising rates of chronic illnesses and cancer-related deaths will support the expansion of pegylated medications on the market. Overview of Market Segments The PEGylated Drugs Market is divided into three segments: region, indication, and molecule. The market has been divided into three segments based on molecules: liposomes, lipid nanoparticles (LNP), macromolecular drugs, and small molecular drugs. The global market for pegylated pharmaceuticals has been divided into several segments based on their respective applications, including autoimmune diseases, neurology, oncology, and hematology. The market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies based on the distribution route. Analysis by region The global market for PEGylated drugs has been divided into four segments based on geography: North America, Europe, Asia-Pacific, and the rest of the world. The greatest market share in 2024 was held by North America, which is expected to grow to USD 8,969.41 million by 2035. Nonetheless, over the course of the forecast period, Asia-Pacific is anticipated to develop at the highest CAGR of 7.03%. North America and South America make up the American market. The North American market is dominated by the United States and Canada. The market is expanding due to the increased occurrence of chronic illnesses like cancer. The European government's investment and assistance in the fight against chronic illnesses is what is propelling the regional market's expansion. Western Europe and Eastern Europe are two further classifications for the European region. The United Kingdom, Italy, France, Spain, and the rest of Western Europe are also included in this category. Key players Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Biogen, BioMarin Pharmaceutical Inc., Coherus BioSciences, Enzon, and Leadiant Biosciences, Inc. are the companies that are involved in the PEGylated Drugs Market.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY .............................................................................................................. 18 2 MARKET INTRODUCTION ............................................................................................................ 20 2.1 DEFINITION ........................................................................................................................................... 20 2.2 SCOPE OF THE STUDY ......................................................................................................................... 20 2.3 RESEARCH OBJECTIVE ........................................................................................................................ 20 2.4 MARKET STRUCTURE .......................................................................................................................... 21 3 RESEARCH METHODOLOGY ...................................................................................................... 22 3.1 OVERVIEW ............................................................................................................................................. 22 3.2 DATA FLOW ........................................................................................................................................... 24 3.2.1 DATA MINING PROCESS ................................................................................................................... 24 3.3 PURCHASED DATABASE: .................................................................................................................... 25 3.4 SECONDARY SOURCES: ....................................................................................................................... 26 3.4.1 SECONDARY RESEARCH DATA FLOW: ............................................................................................... 27 3.5 PRIMARY RESEARCH: .......................................................................................................................... 28 3.5.1 PRIMARY RESEARCH DATA FLOW: ................................................................................................... 29 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ........................................................... 30 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE .................................................................................... 30 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................... 31 3.6.1 REVENUE ANALYSIS APPROACH ...................................................................................................... 31 3.7 DATA FORECASTING ........................................................................................................................... 32 3.7.1 DATA FORECASTING TYPE ............................................................................................................... 32 3.8 DATA MODELING ................................................................................................................................. 33 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............................................................................................. 33 3.8.2 DATA MODELING:............................................................................................................................. 34 3.9 TEAMS AND ANALYST CONTRIBUTION .......................................................................................... 37 4 MARKET DYNAMICS .................................................................................................................... 39 4.1 INTRODUCTION .................................................................................................................................... 39 4.2 DRIVERS ................................................................................................................................................. 40 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ............................................................................ 40 4.2.2 ADVANCEMENTS IN BIOLOGICS ....................................................................................................... 40 4.2.3 RECENTLY APPROVED PEGYLATED DRUGS ....................................................................................... 40 4.3 RESTRAINTS ........................................................................................................................................... 42 4.3.1 HIGH PRODUCTION COSTS ............................................................................................................... 42 4.3.2 REGULATORY HURDLES .................................................................................................................... 43 4.3.3 POTENTIAL SIDE EFFECTS................................................................................................................ 43 4.4 OPPORTUNITY ...................................................................................................................................... 44 4.4.1 EMERGING MARKETS ....................................................................................................................... 44 4.4.2 INNOVATIVE DRUG DELIVERY SYSTEMS ........................................................................................... 45 4.4.3 PERSONALIZED MEDICINE ................................................................................................................ 45 5 MARKET FACTOR ANALYSIS ...................................................................................................... 46 5.1 PORTER'S FIVE FORCES MODEL ........................................................................................................ 46 5.1.1 THREAT OF NEW ENTRANTS ............................................................................................................ 46 5.1.2 BARGAINING POWER OF SUPPLIERS ................................................................................................. 47 5.1.3 THREAT OF SUBSTITUTES ................................................................................................................ 47 5.1.4 BARGAINING POWER OF BUYERS ...................................................................................................... 47 5.1.5 INTENSITY OF RIVALRY .................................................................................................................... 47 5.2 IMPACT OF COVID-19 ON THE GLOBAL PEGYLATED DRUGS MARKET .................................. 48 5.3 QUALITATIVE ANALYSIS ON ANTI-PEG ANTIBODIES AND IMPACT ON PEGYLATED DRUGS 50 6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE .......................................................... 52 6.1 OVERVIEW ............................................................................................................................................. 52 6.2 MACROMOLECULAR DRUGS ............................................................................................................. 54 6.2.1 PROTEIN AND PEPTIDE .................................................................................................................... 55 6.2.2 ENZYME .......................................................................................................................................... 56 6.2.3 APTAMER ........................................................................................................................................ 56 6.3 SMALL MOLECULAR DRUGS .............................................................................................................. 57 6.4 LIPID NANOPARTICLES (LNP) AND LIPOSOMES ........................................................................... 57 7 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION ...................................................... 58 7.1 OVERVIEW ............................................................................................................................................. 58 7.2 ONCOLOGY ............................................................................................................................................ 61 7.3 NEUROLOGY .......................................................................................................................................... 61 7.4 AUTOIMMUNE DISEASES .................................................................................................................... 62 7.5 HAEMATOLOGY ................................................................................................................................... 62 7.6 OTHERS ................................................................................................................................................... 63 8 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CAHNNEL .................................. 64 8.1 OVERVIEW ............................................................................................................................................. 64 8.2 HOSPITAL PHARMACY ....................................................................................................................... 66 8.3 ONLINE PHARMACY ............................................................................................................................ 66 8.4 RETAIL PHARMACY ............................................................................................................................. 67 9 GLOBAL PEGYLATED DRUGS MARKET, BY REGION ............................................................... 68 9.1 OVERVIEW ............................................................................................................................................. 68 9.2 NORTH AMERICA ................................................................................................................................. 70 9.2.1 US ................................................................................................................................................... 74 9.2.2 CANADA .......................................................................................................................................... 76 9.3 EUROPE ................................................................................................................................................... 78 9.3.1 GERMANY ........................................................................................................................................ 82 9.3.2 FRANCE ........................................................................................................................................... 84 9.3.3 UK ................................................................................................................................................... 85 9.3.4 ITALY ............................................................................................................................................... 87 9.3.5 SPAIN .............................................................................................................................................. 89 9.3.6 REST OF EUROPE ............................................................................................................................. 91 9.4 ASIA-PACIFIC ........................................................................................................................................ 93 9.4.1 CHINA ............................................................................................................................................. 96 9.4.2 INDIA ............................................................................................................................................... 98 9.4.3 JAPAN ............................................................................................................................................. 100 9.4.4 AUSTRALIA ...................................................................................................................................... 101 9.4.5 SOUTH KOREA ................................................................................................................................. 103 9.4.6 REST OF ASIA-PACIFIC ..................................................................................................................... 104 9.5 REST OF THE WORLD .......................................................................................................................... 107 9.5.1 MIDDLE EAST & AFRICA ................................................................................................................... 110 9.5.2 SOUTH AMERICA.............................................................................................................................. 112 9.5.2.1 BRAZIL ..................................................................................................................................... 114 9.5.2.2 MEXICO .................................................................................................................................... 115 9.5.2.3 ARGENTINA .............................................................................................................................. 117 9.5.2.4 REST OF SOUTH AMERICA ........................................................................................................ 119 10 COMPETITIVE LANDSCAPE ........................................................................................................ 122 10.1 INTRODUCTION .................................................................................................................................... 122 10.2 MARKET SHARE ANALYSIS, 2024 ...................................................................................................... 122 10.3 COMPETITOR DASHBOARD ............................................................................................................... 123 10.4 PUBLIC PLAYERS STOCK SUMMARY ................................................................................................ 124 10.5 CMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ................................................................... 125 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ........................................................................... 126 10.6.1 PRODUCT APPROVAL ....................................................................................................................... 126 10.6.2 PRODUCT EXPANSION ..................................................................................................................... 127 10.6.3 APPROVAL DENIED .......................................................................................................................... 127 10.6.4 PRODUCT DISCONTINUATION........................................................................................................... 127 10.6.5 AGREEMENT/ACQUISITION .............................................................................................................. 128 10.6.6 CLINICAL TRIAL FINDINGS ............................................................................................................... 128 11 COMPANY PROFILES .................................................................................................................. 129 11.1 AMGEN INC. ........................................................................................................................................... 129 11.1.1 COMPANY OVERVIEW ...................................................................................................................... 129 11.1.2 FINANCIAL OVERVIEW...................................................................................................................... 130 11.1.3 PRODUCTS OFFERED ........................................................................................................................ 131 11.1.4 KEY DEVELOPMENTS ....................................................................................................................... 131 11.1.5 SWOT ANALYSIS .............................................................................................................................. 132 11.1.6 KEY STRATEGIES ............................................................................................................................. 132 11.2 PFIZER INC. ............................................................................................................................................ 133 11.2.1 COMPANY OVERVIEW ...................................................................................................................... 133 11.2.2 FINANCIAL OVERVIEW...................................................................................................................... 135 11.2.3 PRODUCTS OFFERED ........................................................................................................................ 136 11.2.4 KEY DEVELOPMENTS ....................................................................................................................... 136 11.2.5 SWOT ANALYSIS .............................................................................................................................. 136 11.2.6 KEY STRATEGIES ............................................................................................................................. 137 11.3 BIOGEN ................................................................................................................................................... 138 11.3.1 COMPANY OVERVIEW ...................................................................................................................... 138 11.3.2 FINANCIAL OVERVIEW...................................................................................................................... 139 11.3.3 PRODUCTS OFFERED ........................................................................................................................ 140 11.3.4 KEY DEVELOPMENTS ....................................................................................................................... 140 11.3.5 KEY STRATEGIES ............................................................................................................................. 140 11.4 BAYER AG ............................................................................................................................................... 141 11.4.1 COMPANY OVERVIEW ...................................................................................................................... 141 11.4.2 FINANCIAL OVERVIEW...................................................................................................................... 142 11.4.3 PRODUCTS OFFERED ........................................................................................................................ 142 11.4.4 KEY DEVELOPMENTS ....................................................................................................................... 143 11.4.5 SWOT ANALYSIS .............................................................................................................................. 143 11.4.6 KEY STRATEGY ................................................................................................................................ 144 11.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED....................................................................... 145 11.5.1 COMPANY OVERVIEW ..................................................................................................................... 145 11.5.2 FINANCIAL OVERVIEW...................................................................................................................... 146 11.5.3 PRODUCT OFFERED .......................................................................................................................... 146 11.5.4 KEY DEVELOPMENTS ....................................................................................................................... 147 11.5.5 KEY STRATEGIES ............................................................................................................................. 147 11.6 NOVO NORDISK A/S ............................................................................................................................. 148 11.6.1 COMPANY OVERVIEW ...................................................................................................................... 148 11.6.2 FINANCIAL OVERVIEW...................................................................................................................... 149 11.6.3 PRODUCTS OFFERED ........................................................................................................................ 150 11.6.4 KEY DEVELOPMENTS ....................................................................................................................... 150 11.6.5 SWOT ANALYSIS .............................................................................................................................. 151 11.6.6 KEY STRATEGIES ............................................................................................................................. 151 11.7 SANDOZ GROUP AG ............................................................................................................................. 152 11.7.1 COMPANY OVERVIEW ...................................................................................................................... 152 11.7.2 FINANCIAL OVERVIEW...................................................................................................................... 153 11.7.3 PRODUCTS OFFERED ........................................................................................................................ 154 11.7.4 KEY DEVELOPMENTS ....................................................................................................................... 154 11.7.5 KEY STRATEGIES ............................................................................................................................. 154 11.8 ASTRAZENECA ...................................................................................................................................... 155 11.8.1 COMPANY OVERVIEW ...................................................................................................................... 155 11.8.2 FINANCIAL OVERVIEW...................................................................................................................... 156 11.8.3 PRODUCTS OFFERED ........................................................................................................................ 157 11.8.4 KEY DEVELOPMENTS ....................................................................................................................... 157 11.8.5 KEY STRATEGIES ............................................................................................................................. 157 11.9 COHERUS BIOSCIENCES, INC. ............................................................................................................ 158 11.9.1 COMPANY OVERVIEW ...................................................................................................................... 158 11.9.2 FINANCIAL OVERVIEW...................................................................................................................... 159 11.9.3 PRODUCTS OFFERED ........................................................................................................................ 160 11.9.4 KEY DEVELOPMENTS ....................................................................................................................... 160 11.9.5 KEY STRATEGIES ............................................................................................................................. 160 11.10 F. HOFFMANN-LA ROCHE LTD. ......................................................................................................... 161 11.10.1 COMPANY OVERVIEW .......................................................................................................... 161 11.10.2 FINANCIAL OVERVIEW ......................................................................................................... 162 11.10.3 PRODUCTS OFFERED ........................................................................................................... 163 11.10.4 KEY DEVELOPMENTS ........................................................................................................... 163 11.10.5 SWOT ANALYSIS ................................................................................................................. 163 11.10.6 KEY STRATEGIES ................................................................................................................. 164 11.11 JOHNSON & JOHNSON INC. ................................................................................................................ 165 11.11.1 COMPANY OVERVIEW .......................................................................................................... 165 11.11.2 FINANCIAL OVERVIEW ......................................................................................................... 166 11.11.3 PRODUCTS OFFERED ........................................................................................................... 167 11.11.4 KEY DEVELOPMENTS ........................................................................................................... 167 11.11.5 SWOT ANALYSIS ................................................................................................................. 167 11.11.6 KEY STRATEGIES ................................................................................................................. 168 11.12 ALNYLAM PHARMACEUTICALS, INC. .............................................................................................. 169 11.12.1 COMPANY OVERVIEW .......................................................................................................... 169 11.12.2 FINANCIAL OVERVIEW ......................................................................................................... 170 11.12.3 PRODUCTS OFFERED ........................................................................................................... 170 11.12.4 KEY DEVELOPMENTS ........................................................................................................... 171 11.12.5 KEY STRATEGIES ................................................................................................................. 171 11.13 LES LABORATOIRES SERVIER ............................................................................................................ 172 11.13.1 COMPANY OVERVIEW .......................................................................................................... 172 11.13.2 FINANCIAL OVERVIEW ......................................................................................................... 172 11.13.3 PRODUCT OFFERED ............................................................................................................. 173 11.13.4 KEY DEVELOPMENTS ........................................................................................................... 173 11.13.5 KEY STRATEGIES ................................................................................................................. 173 12 DATA CITATIONS ......................................................................................................................... 174
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 34 TABLE 2 RECENTLY APPROVED PEGYLATED DRUGS IN U.S., AUSTRALIA, JAPAN, AND CANADA 41 TABLE 3 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 53 TABLE 4 GLOBAL PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY REGION, 2019–2035 (USD MILLION) 54 TABLE 5 GLOBAL PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 55 TABLE 6 GLOBAL PEGYLATED DRUGS MARKET, FOR PROTEIN AND PEPTIDE, BY REGION, 2019–2035 (USD MILLION) 55 TABLE 7 GLOBAL PEGYLATED DRUGS MARKET, FOR ENZYME, BY REGION, 2019–2035 (USD MILLION) 56 TABLE 8 GLOBAL PEGYLATED DRUGS MARKET, FOR APTAMER, BY REGION, 2019–2035 (USD MILLION) 56 TABLE 9 GLOBAL PEGYLATED DRUGS MARKET, FOR SMALL MOLECULAR DRUGS, BY REGION, 2019–2035 (USD MILLION) 57 TABLE 10 GLOBAL PEGYLATED DRUGS MARKET, FOR LIPID NANOPARTICLES (LNP) AND LIPOSOMES, BY REGION, 2019–2035 (USD MILLION) 57 TABLE 11 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 60 TABLE 12 GLOBAL PEGYLATED DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019–2035 (USD MILLION) 61 TABLE 13 GLOBAL PEGYLATED DRUGS MARKET, FOR NEUROLOGY, BY REGION, 2019–2035 (USD MILLION) 61 TABLE 14 GLOBAL PEGYLATED DRUGS MARKET, FOR AUTOIMMUNE DISEASES, BY REGION, 2019–2035 (USD MILLION) 62 TABLE 15 GLOBAL PEGYLATED DRUGS MARKET, FOR HAEMATOLOGY, BY REGION, 2019–2035 (USD MILLION) 62 TABLE 16 GLOBAL PEGYLATED DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD MILLION) 63 TABLE 17 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 65 TABLE 18 GLOBAL PEGYLATED DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019–2035 (USD MILLION) 66 TABLE 19 GLOBAL PEGYLATED DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019–2035 (USD MILLION) 66 TABLE 20 GLOBAL PEGYLATED DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019–2035 (USD MILLION) 67 TABLE 21 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2019–2035 (USD MILLION) 69 TABLE 22 NORTH AMERICA PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 71 TABLE 23 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 72 TABLE 24 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 73 TABLE 25 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 73 TABLE 26 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 74 TABLE 27 US: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 74 TABLE 28 US: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 74 TABLE 29 US: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 75 TABLE 30 US: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 75 TABLE 31 CANADA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 76 TABLE 32 CANADA: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 76 TABLE 33 CANADA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 77 TABLE 34 CANADA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 77 TABLE 35 EUROPE PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 79 TABLE 36 EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 80 TABLE 37 EUROPE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 80 TABLE 38 EUROPE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 81 TABLE 39 EUROPE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 81 TABLE 40 GERMANY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 82 TABLE 41 GERMANY: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 82 TABLE 42 GERMANY: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 83 TABLE 43 GERMANY: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 83 TABLE 44 FRANCE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 84 TABLE 45 FRANCE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 84 TABLE 46 FRANCE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 84 TABLE 47 FRANCE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 85 TABLE 48 UK: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 85 TABLE 49 UK: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 86 TABLE 50 UK: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 86 TABLE 51 UK: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 86 TABLE 52 ITALY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 87 TABLE 53 ITALY: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 87 TABLE 54 ITALY: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 88 TABLE 55 ITALY: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 88 TABLE 56 SPAIN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 89 TABLE 57 SPAIN: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 89 TABLE 58 SPAIN: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 90 TABLE 59 SPAIN: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 90 TABLE 60 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 91 TABLE 61 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 91 TABLE 62 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 92 TABLE 63 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 92 TABLE 64 ASIA-PACIFIC PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 94 TABLE 65 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 95 TABLE 66 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 95 TABLE 67 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 95 TABLE 68 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 96 TABLE 69 CHINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 96 TABLE 70 CHINA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 97 TABLE 71 CHINA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 97 TABLE 72 CHINA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 97 TABLE 73 INDIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 98 TABLE 74 INDIA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 98 TABLE 75 INDIA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 99 TABLE 76 INDIA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 99 TABLE 77 JAPAN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 100 TABLE 78 JAPAN: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 100 TABLE 79 JAPAN: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 100 TABLE 80 JAPAN: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 101 TABLE 81 AUSTRALIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 101 TABLE 82 AUSTRALIA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 102 TABLE 83 AUSTRALIA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 102 TABLE 84 AUSTRALIA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 102 TABLE 85 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 103 TABLE 86 SOUTH KOREA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 103 TABLE 87 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 104 TABLE 88 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 104 TABLE 89 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 104 TABLE 90 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 105 TABLE 91 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 105 TABLE 92 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 106 TABLE 93 REST OF THE WORLD PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 108 TABLE 94 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 108 TABLE 95 REST OF THE WORLD: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 109 TABLE 96 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 109 TABLE 97 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 109 TABLE 98 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 110 TABLE 99 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 110 TABLE 100 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 111 TABLE 101 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 111 TABLE 102 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 112 TABLE 103 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 112 TABLE 104 SOUTH AMERICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 112 TABLE 105 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 113 TABLE 106 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 113 TABLE 107 BRAZIL: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 114 TABLE 108 BRAZIL: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 114 TABLE 109 BRAZIL: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 115 TABLE 110 BRAZIL: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 115 TABLE 111 MEXICO: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 115 TABLE 112 MEXICO: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 116 TABLE 113 MEXICO: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 116 TABLE 114 MEXICO: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 117 TABLE 115 ARGENTINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 117 TABLE 116 ARGENTINA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 117 TABLE 117 ARGENTINA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 118 TABLE 118 ARGENTINA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 118 TABLE 119 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 119 TABLE 120 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 119 TABLE 121 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 120 TABLE 122 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 120 TABLE 123 PRODUCT APPROVAL 126 TABLE 124 PRODUCT EXPANSION 127 TABLE 125 APPROVAL DENIED 127 TABLE 126 PRODUCT DISCONTINUATION 127 TABLE 127 AGREEMENT/ACQUISITION 128 TABLE 128 CLINICAL TRIAL FINDINGS 128 TABLE 129 AMGEN INC.: PRODUCTS OFFERED 131 TABLE 130 AMGEN INC.: KEY DEVELOPMENTS 131 TABLE 131 PFIZER INC.: PRODUCTS OFFERED 136 TABLE 132 PFIZER INC.: KEY DEVELOPMENTS 136 TABLE 133 BIOGEN: PRODUCTS OFFERED 140 TABLE 134 BIOGEN: KEY DEVELOPMENTS 140 TABLE 135 BAYER AG: PRODUCTS OFFERED 142 TABLE 136 BAYER AG: KEY DEVELOPMENTS 143 TABLE 137 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED 146 TABLE 138 TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY DEVELOPMENTS 147 TABLE 139 NOVO NORDISK A/S: PRODUCTS OFFERED 150 TABLE 140 NOVO NORDISK A/S: KEY DEVELOPMENTS 150 TABLE 141 SANDOZ GROUP AG: PRODUCTS OFFERED 154 TABLE 142 SANDOZ GROUP AG: KEY DEVELOPMENTS 154 TABLE 143 ASTRAZENECA: PRODUCTS OFFERED 157 TABLE 144 ASTRAZENECA: KEY DEVELOPMENTS 157 TABLE 145 COHERUS BIOSCIENCES, INC.: PRODUCTS OFFERED 160 TABLE 146 COHERUS BIOSCIENCES, INC.: KEY DEVELOPMENTS 160 TABLE 147 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 163 TABLE 148 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED 167 TABLE 149 ALNYLAM PHARMACEUTICALS, INC: PRODUCTS OFFERED 170 TABLE 150 ALNYLAM PHARMACEUTICALS, INC: KEY DEVELOPMENTS 171 TABLE 151 LES LABORATOIRES SERVIER: PRODUCTS OFFERED 173 LIST OF FIGURES FIGURE 1 GLOBAL PEGYLATED DRUGS MARKET: STRUCTURE 21 FIGURE 2 GLOBAL PEGYLATED DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035) 39 FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035) 42 FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035) 44 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PEGYLATED DRUGS MARKET 46 FIGURE 6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2024 & 2035 (USD MILLION) 53 FIGURE 7 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY MOLECULE, 2024 54 FIGURE 8 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION) 59 FIGURE 9 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY APPLICATION, 2024 60 FIGURE 10 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD MILLION) 64 FIGURE 11 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024 65 FIGURE 12 GLOBAL PEGYLATED DRUGS MARKET SHARE, BY REGION, 2024 & 2035 (USD MILLION) 68 FIGURE 13 GLOBAL PEGYLATED DRUGS MARKET SHARE, BY REGION, 2024 (%) 69 FIGURE 14 NORTH AMERICA PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 71 FIGURE 15 NORTH AMERICA PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 72 FIGURE 16 EUROPE PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 78 FIGURE 17 EUROPE PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 79 FIGURE 18 ASIA-PACIFIC PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 93 FIGURE 19 ASIA-PACIFIC PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 94 FIGURE 20 REST OF THE WORLD PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 107 FIGURE 21 REST OF THE WORLD PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 108 FIGURE 22 GLOBAL PEGYLATED DRUGS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024 122 FIGURE 23 COMPETITOR DASHBOARD: GLOBAL PEGYLATED DRUGS MARKET 123 FIGURE 24 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 130 FIGURE 25 AMGEN INC.: SWOT ANALYSIS 132 FIGURE 26 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 135 FIGURE 27 PFIZER INC.: SWOT ANALYSIS 136 FIGURE 28 BIOGEN: FINANCIAL OVERVIEW SNAPSHOT 139 FIGURE 29 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 142 FIGURE 30 BAYER AG: SWOT ANALYSIS 143 FIGURE 31 TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL OVERVIEW SNAPSHOT 146 FIGURE 32 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT 149 FIGURE 33 NOVO NORDISK A/S: SWOT ANALYSIS 151 FIGURE 34 SANDOZ GROUP AG: FINANCIAL OVERVIEW SNAPSHOT 153 FIGURE 35 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 156 FIGURE 36 COHERUS BIOSCIENCES, INC.: FINANCIAL OVERVIEW SNAPSHOT 159 FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT 162 FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 163 FIGURE 39 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT 166 FIGURE 40 JOHNSON & JOHNSON INC.: SWOT ANALYSIS 167 FIGURE 41 ALNYLAM PHARMACEUTICALS, INC: FINANCIAL OVERVIEW SNAPSHOT 170

提及公司

Horizon Therapeutics PlcF. Hoffmann-La Roche Ltd.Pfizer Inc.Novo Nordisk A/SUCB S.A.AmgenInc.AstraZeneca.Merck & Co.Inc.Takeda Pharmaceutical Company LimitedBayer AGBiogenBioMarin Pharmaceutical IncCoherus BioSciencesEnzonand Leadiant BiosciencesInc.

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們